

## **IMI consultation on advanced therapies**

### **Response from Prof. Christof von Kalle and Dr. Manfred Schmidt**

Dear Sir or Madam,

on behalf of Prof. Christof von Kalle and Dr. Manfred Schmidt (National Center for Tumor Diseases, Heidelberg, Germany and the German Cancer Research Center, Heidelberg, Germany) I would like to add following comment to the ongoing consultation on the IMI Advanced Therapies Concept Paper:

„We would advise to consider on-/off-target specificity when discussing gene editing.” (personal capacity)

Thank you very much for your consideration.

With best regards,

Klara Gießler

Klara Gießler, PhD

Scientific Coordinator NCT

National Center for Tumor Diseases (NCT)

German Cancer Research Center (DKFZ)

NCT Heidelberg

Im Neuenheimer Feld 460

69120 Heidelberg

Germany

[www.nct-heidelberg.de](http://www.nct-heidelberg.de)